ELANCO UK AH LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +3.5%

  £331,449,000 → £342,988,000

• Cash

  +61.8%

  £21,691,000 → £35,097,000

• Net assets

  +5.9%

  £114,005,000 → £120,699,000

• Employees

  +21.7%

  272 → 331

• Operating profit

  -29.5%

  £16,740,000 → £11,798,000

• Profit before tax

  -32.1%

  £13,535,000 → £9,195,000

• Wages

  +25.1%

  £22,621,000 → £28,298,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Ernst & Young

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The directors have assessed the ability of Elanco Animal Health Incorporated to provide the level of support that might be required and see no reason to believe that a material uncertainty exists that may cast significant doubt about the ability of Elanco UK AH Limited to continue as a going concern. On the basis of their assessment of the company's financial position, the Company's Directors have a reasonable expectation that the company will be able to continue in operational existence for the foreseeable future.”

Group structure

1. ELANCO UK AH LIMITED · parent
   1. Dista Products Limited 100% · UK · Ordinary share Capital
   2. Elanco Europe Limited 100% · UK · Ordinary share Capital
   3. Vericore Limited 100% · UK · Ordinary share Capital
   4. Elanco Animal Health UK Limited 100% · UK · Ordinary share Capital
   5. Elanco Animal Vaccines Limited 100% · UK · Ordinary share Capital

Significant events

• “In July 2024, Elancó globally completed the sale of its Aqua portfolio to Merck for $1.3bn, the proceeds of which contributed to debt paydown. For Elanco UK, Aqua was a relatively small business unit and has resulted in a reduction in annualised revenues of approximately £6.5m.”
• “In November 2024, the Company acquired a manufacturing facility in Speke, Liverpool which was owned and operated by a third party contract manufacturer until its administration in the 2nd half of 2024... result[ing] in our decision to acquire this manufacturing facility, safeguarding product supply and the employment of approximately 260 people...”
• “Under the UK Emissions Trading Scheme Order, the Company's Speke facility... had a failure to acquire and surrender credits... resulting in an outstanding liability to the Environment Agency (EA)... The legal basis for such a transfer is highly uncertain. The Company is cooperating with the EA... to demonstrate that it should not be held liable for costs incurred before the acquisition date.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

5

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.